Form 8-K - Current report:
SEC Accession No. 0001104659-24-117214
Filing Date
2024-11-13
Accepted
2024-11-13 07:06:30
Documents
14
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2428175d1_8k.htm   iXBRL 8-K 25333
2 EXHIBIT 99.1 tm2428175d1_ex99-1.htm EX-99.1 62365
  Complete submission text file 0001104659-24-117214.txt   271058

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE acxp-20241113_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acxp-20241113_pre.xml EX-101.PRE 22365
5 XBRL TAXONOMY EXTENSION SCHEMA acxp-20241113.xsd EX-101.SCH 3024
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2428175d1_8k_htm.xml XML 3685
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40536 | Film No.: 241451146
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)